Compare
Side by side
Pick up to three peptides to see how their mechanisms, studied uses and evidence levels differ. Rows where the entries disagree are marked with a blue edge.
Selected 1 of 3
Comparison
Lanreotide
Bone & endocrine
Evidence level
Strong evidence
Approval status
Approved drug
Mechanism of action
- 1.Binds SSTR2 and SSTR5, suppressing growth hormone and gut hormone secretion.
- 2.Reduces tumour hormone output in functioning neuroendocrine tumours.
- 3.Has direct antiproliferative effects on somatostatin-receptor-positive tumour cells.
- 4.Slows gut transit and reduces secretion.
- 5.The gel depot maintains steady levels between four-weekly injections.
Studied for
- Acromegaly
- Gastroenteropancreatic neuroendocrine tumours (CLARINET)
- Carcinoid syndrome symptom control (ELECT)
- Thyrotrophic pituitary adenoma
Reported effects
- Biochemical control of growth hormone and IGF-1 in a large share of acromegaly patients
- CLARINET showed significantly longer progression-free survival than placebo in gastroenteropancreatic tumours
- Reduced flushing and diarrhoea in carcinoid syndrome
- Shrinkage of the gallbladder and gallstone formation
Side effects
- Gallstones and biliary sludge
- Diarrhoea and abdominal pain
- Injection-site nodules and pain
- Hyperglycaemia
- Bradycardia
- Fatigue
Research protocol
Research context only - prescription medicine. Lanreotide autogel is given as 60 to 120 mg deep subcutaneously every 28 days for acromegaly, or 120 mg every 28 days for neuroendocrine tumours, with dose guided by growth hormone and IGF-1 levels. CLARINET followed participants for a median of 96 weeks with imaging every 12 weeks.
Research context only
Evidence justification
Randomised placebo-controlled trials in both indications, including CLARINET with progression-free survival as a pre-specified primary endpoint.